Functional group interactions of a 5-HT3R antagonist.
BACKGROUND
Lerisetron, a competitive serotonin type 3 receptor (5-HT3R) antagonist, contains five functional groups capable of interacting with amino acids in the 5-HT3R binding site. Site directed mutagenesis studies of the 5-HT3AR have revealed several amino acids that are thought to form part of the binding domain of this receptor. The specific functional groups on the ligand that interact with these amino acids are, however, unknown. Using synthetic analogs of lerisetron as molecular probes in combination with site directed mutagenesis, we have identified some of these interactions and have proposed a model of the lerisetron binding site.


RESULTS
Two analogs of lerisetron were synthesized to probe 5-HT3R functional group interactions with this compound. Analog 1 lacks the N1 benzyl group of lerisetron and analog 2 contains oxygen in place of the distal piperazine nitrogen. Both analogs show significantly decreased binding affinity to wildtype 5-HT3ASRs. Mutations at W89, R91, Y142 and Y152 produced significant decreases in binding compared to wildtype receptors. Binding affinities of analogs 1 and 2 were altered only by mutations at W89, and Y152.


CONCLUSIONS
Based on the data obtained for lerisetron and analogs 1 and 2, we have proposed a tentative model of the lerisetron binding pocket of the 5-HT3ASR. According to this model, The N-benzyl group interacts in a weak interaction with R91 while the benzimidazole group interacts with W89. Our data support an interaction of the distal amino nitrogen with Y142 and Y152.
Venkataraman
Padmavati
P
Department of Neurobiology and Physiology, Northwestern University, Evanston, IL 60208-3520, USA. padma964@hotmail.com
Joshi
Prasad
P
Venkatachalan
Srinivasan P
SP
Muthalagi
Mani
M
Parihar
Harish S
HS
Kirschbaum
Karen S
KS
Schulte
Marvin K
MK
D000818:Animals; D001120:Arginine / Q000502:physiology; D001562:Benzimidazoles / Q000378:metabolism; D001593:Benzyl Compounds / Q000378:metabolism; D002460:Cell Line; D006801:Humans; D007668:Kidney / Q000166:cytology / Q000196:embryology; D051379:Mice; D016297:Mutagenesis, Site-Directed / Q000235:genetics; D009584:Nitrogen / Q000378:metabolism; D018408:Patch-Clamp Techniques; D000077489:Piperazine; D010879:Piperazines / Q000737:chemistry / Q000378:metabolism; D010880:Piperidines / Q000378:metabolism; D011485:Protein Binding / Q000502:physiology; D025941:Protein Interaction Mapping / Q000379:methods*; D011985:Receptors, Serotonin / Q000235:genetics / Q000378:metabolism*; D044406:Receptors, Serotonin, 5-HT3; D012702:Serotonin Antagonists / Q000378:metabolism*; D013329:Structure-Activity Relationship; D014364:Tryptophan / Q000502:physiology; D014443:Tyrosine / Q000502:physiology
D001562:Benzimidazoles; D001593:Benzyl Compounds; D010879:Piperazines; D010880:Piperidines; D011985:Receptors, Serotonin; D044406:Receptors, Serotonin, 5-HT3; D012702:Serotonin Antagonists; D000077489:Piperazine; D014443:Tyrosine; D014364:Tryptophan; D001120:Arginine; D009584:Nitrogen; C115094:lerisetron